Antibodies have become the top-selling class of therapeutics stemming from their high level of specificity and affinity for disease proteins as well as their ability to target diverse molecules with a wide array of mechanisms of action and high suitability for industrial manufacturing . Soluble factor deficiency has broad therapeutic implications across rare/metabolic diseases and oncology. Aeterna has developed a novel concept utilizing unique properties of antibody therapeutics to offer effective treatment regimens for indications involving deficiency of short lived factors. Based on our strategy and our unique technological expertise, an administration of non-neutralizing antibodies results in accumulation of active complexes leading to pathway agonism of the targeted ligand. Such an approach represents a compelling means of therapeutic intervention with potentially broad applicability across human disease.